---
document_datetime: 2023-09-21 17:12:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/novomix-epar-procedural-steps-taken-authorisation_en.pdf
document_name: novomix-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3719804
conversion_datetime: 2025-12-24 18:22:15.209514
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Novo Nordisk A/S, Denmark submitted on 2 September 1999 to the European Agency for the Evaluation of Medicinal Products (EMEA), an application to obtain a marketing authorisation in accordance with the Centralised Procedure for the medicinal product NovoMix 30 (insulin aspart) falling within the scope of Part A of the Annex to Council Regulation No (EC) 2309/93.

NovoMix 30 is a mixture of 30% soluble insulin aspart and 70% insulin aspart protamine crystals.

On  7  September  1999,  a  Community  Marketing  Authorisation  has  been  granted  for  100%  soluble insulin aspart, named NovoRapid (EU/1/99/119/001-008). In order to avoid misleading information on the release profile of the mixture, the applicant wishes to market the mixture under a different name ('NovoMix 30' instead of 'NovoRapid'). On this basis, a separate full application in accordance with Directive 65/65/EEC, as described in the Notice to Applicants, was submitted.

The CPMP appointed the Rapporteur and Co-Rapporteur as follows:

Rapporteur:

Dr. Per Sj√∂berg

Dr. Per Nilsson

Co-Rapporteur:

Dr. Gorm Jensen

Dr. Mark Ainsworth

## Licensing status:

The product was not licensed in any country inside or outside the EU at the time of submission of the application.

## 2. Steps taken for the assessment of the product

- The procedure started on 24 September 1999.
- The  Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 30 November 1999.
- The  Co-Rapporteur's  first  assessment  report  was  circulated  to  all  members  of  the  CPMP  on 2 December 1999.
- During  its  meeting  on  18-20  January  2000,  the  CPMP  agreed  on  the  consolidated  list  of questions to be sent to the applicant on 18 January 2000.
- The applicant submitted the responses to the consolidated list of questions on 8 February 2000.
- The Rapporteur and the Co-Rapporteur circulated the joint response assessment report on the applicant's responses to the list of questions to all CPMP members on 10 March 2000.
- During the meeting on 11-13 April 2000 the CPMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation for the different NovoMix 30 presentations on 13 April 2000.